Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Kidney Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

  • Details

ClinicalTrials.gov ID: NCT03785249
Diagnosis Type: NA
USOR Number: 19151

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy (MM-398-01-03-04)

  • Details

ClinicalTrials.gov ID: NCT03088813
Diagnosis Type: NA
USOR Number: 17099

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Solid Tumors

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)

  • Details

ClinicalTrials.gov ID: NCT04083976
Diagnosis Type: NA
USOR Number: 19092

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)

  • Details

ClinicalTrials.gov ID: NCT03600883
Diagnosis Type: NA
USOR Number: 19024

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Pancreatic Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)

  • Details

ClinicalTrials.gov ID: NCT03600883
Diagnosis Type: NA
USOR Number: 19024

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Solid Tumors

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)

  • Details

ClinicalTrials.gov ID: NCT03600883
Diagnosis Type: NA
USOR Number: 19024

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)

  • Details

ClinicalTrials.gov ID: NCT03600883
Diagnosis Type: NA
USOR Number: 19024

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Colon Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)

  • Details

ClinicalTrials.gov ID: NCT03600883
Diagnosis Type: NA
USOR Number: 19024

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Endometrial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)

  • Details

ClinicalTrials.gov ID: NCT03600883
Diagnosis Type: NA
USOR Number: 19024

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Lymphomas

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

  • Details

ClinicalTrials.gov ID: NCT03206918
Diagnosis Type: NA
USOR Number: 18263

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Leukemia

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

  • Details

ClinicalTrials.gov ID: NCT03206918
Diagnosis Type: NA
USOR Number: 18263

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Lymphomas

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents (D8220R00004)

  • Details

ClinicalTrials.gov ID: NCT03816683
Diagnosis Type: NA
USOR Number: 18127

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

  • Details

ClinicalTrials.gov ID: NCT03955913
Diagnosis Type: NA
USOR Number: 19032

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

  • Details

ClinicalTrials.gov ID: NCT03955913
Diagnosis Type: NA
USOR Number: 19032

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: NA
USOR Number: 19054

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

  • Details

ClinicalTrials.gov ID: NCT03390504
Diagnosis Type: NA
USOR Number: 17133

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer (SGNLVA-002)

  • Details

ClinicalTrials.gov ID: NCT03310957
Diagnosis Type: NA
USOR Number: 18004

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Biliary Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, Colorado 80220
530.81 mi. away
P: (303) 321-0302

More Details View Practice Page

Pages